From: Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial
 | Crude | Adjusteda | ||
β (95%CI) | p value | β (95%CI) | p value | |
Average scores (0, 6 and 12 months) | ||||
 DAS28-ESR | 0.01 (−0.001, 0.02) | 0.088 | 0.007 (−0.01, 0.02) | 0.306 |
 Pain | 0.73 (0.50, 0.96) | <0.001 | 0.62 (0.36, 0.88) | <0.001 |
 Fatigue | 0.96 (0.68, 1.24) | <0.001 | 0.51 (0.20, 0.82) | 0.001 |
12-month outcomes | ||||
 | Crude Odds ratio (95%CI) | p value | Adjusteda Odds ratio (95%CI) | p value |
 Remission DAS28-ESR (<2.6) | 1.00 (0.97, 1.03) | 0.969 | 1.01 (0.96, 1.03) | 0.808 |
 Change in pain (≥10 units) | 1.01 (0.98, 1.03) | 0.667 | 1.00 (0.98, 1.02) | 0.642 |
 Change in fatigue (≥10 units) | 1.01 (0.99, 1.04) | 0.353 | 1.02 (0.98, 1.04) | 0.387 |